Urinary cell-free mitochondrial and nuclear deoxyribonucleic acid correlates with the prognosis of chronic kidney diseases

Table 2 The levels of different parameters in varying stages of CKD

	Stage 1,2 ^a	Stage 3 ^b	Stage 3 ^c	Stage 4,5 ^d	P value	Post hoc tests
Plasma cf-mtDNA (GE/mL)	523 ± 710	373 ± 360	420 ± 664	112 ± 134	0.209
Plasma cf-nDNA (GE/mL)	1269 ± 1195	698 ± 527	439 ± 569	104 ± 70.01	<0.001**	a > b,c,d
Urine cf-mtDNA (GE/mL)	0.43 ± 0.69	0.98 ± 3.10	2.78 ± 10.12	6.49 ± 17.85	0.220
Urine cf-nDNA (GE/mL)	2.83 ± 4.60	4.49 ± 12.09	15.39 ± 44.01	8.01 ± 12.08	0.351
Plasma NGAL (ng/mL)	394 ± 175	489.6 ± 174.9	744.2 ± 272.1	1096 ± 488.7	<0.001**	a,b,<c,d
MCN (per cell)	90.7 ± 66.9	94.9 ± 77.01	92.9 ± 89.9	110.5 ± 112.7	0.901
Urine 8-OH dG/Cr	3.73 ± 1.81	3.78 ± 2.93	4.15 ± 2.65	2.99 ± 1.53	0.416

P-value by One-Way ANOVA follow with Bonferroni multiple comparisons at type I error of 0.05 level
*P <0.05, **P <0.01
Post hoc ^a indicates group stage 1,2; ^b indicates group stage 3a; ^c indicates group stage 3b; ^d indicates group stage 4,5
MCN mitochondrial copy number, NGAL neutrophil gelatinase-associated lipocalin; 8-OH dG 8-hydroxy-2-deoxyguanosine, cf-mtDNA cell-free mitochondrial DNA, cf-nDNA cell-free nuclear DNA, GE/mL genome equivalents/mL

ISSN: 1471-2369